BIEL - CLEAR PATH TO SUCCESS BIEL is undervalue
Post# of 8405
(Total Views: 144)
Posted On: 06/10/2025 12:12:56 PM
BIEL - CLEAR PATH TO SUCCESS
BIEL is undervalued at just $5 million with $496,000 in revenue (2024), compared to companies that boast billion-dollar valuations despite generating less revenue. For instance, QUBT holds a $2.3 billion market cap on just $373,000 in revenue. As awareness grows around the advantages of PSWT/PEMF technology and the vast multi-billion-dollar, drug-free pain management market—where FDA-cleared ActiPatch, RecoveryRx, and RecoveryRx Veterinary products are poised to lead—BIEL's potential for massive growth becomes undeniable.
In Q3 2021, BIEL achieved profitability with $22,381 in earnings on $414,700 in revenue, including over $100,000 in COVID relief funds. With its exceptionally low operating costs and efficient business model, profitability is within reach. A $1.5 million annual revenue—or a $400,000 quarter—could be the tipping point, potentially driving the stock price to $0.01 and increasing by $0.01 for every additional $2.5 million in annual revenue (P/E = 100). Moreover, the company's $40 million tax-loss carryforward ensures that the first $40 million in profits remain tax-free, accelerating the road to sustained profitability. If management hints at profitability in Q1 2025 or suggests Q2 will be profitable, investor confidence will grow and the PPS would hit COPPER, solving key challenges, and unlocking new opportunities.
BIEL is undervalued at just $5 million with $496,000 in revenue (2024), compared to companies that boast billion-dollar valuations despite generating less revenue. For instance, QUBT holds a $2.3 billion market cap on just $373,000 in revenue. As awareness grows around the advantages of PSWT/PEMF technology and the vast multi-billion-dollar, drug-free pain management market—where FDA-cleared ActiPatch, RecoveryRx, and RecoveryRx Veterinary products are poised to lead—BIEL's potential for massive growth becomes undeniable.
In Q3 2021, BIEL achieved profitability with $22,381 in earnings on $414,700 in revenue, including over $100,000 in COVID relief funds. With its exceptionally low operating costs and efficient business model, profitability is within reach. A $1.5 million annual revenue—or a $400,000 quarter—could be the tipping point, potentially driving the stock price to $0.01 and increasing by $0.01 for every additional $2.5 million in annual revenue (P/E = 100). Moreover, the company's $40 million tax-loss carryforward ensures that the first $40 million in profits remain tax-free, accelerating the road to sustained profitability. If management hints at profitability in Q1 2025 or suggests Q2 will be profitable, investor confidence will grow and the PPS would hit COPPER, solving key challenges, and unlocking new opportunities.
(1)
(0)